In This Article:
Amid ongoing market volatility and tariff uncertainties, the S&P 500 and Dow Jones Industrial Average have experienced significant declines, while the Nasdaq Composite showed a slight increase. For investors willing to explore beyond well-known companies, penny stocks—often associated with smaller or newer enterprises—can present unexpected opportunities. Despite their somewhat outdated label, these stocks remain relevant for those seeking potential growth driven by solid financial health.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
Safe Bulkers (NYSE:SB) | $3.22 | $338.65M | ★★★★☆☆ |
Tuya (NYSE:TUYA) | $2.27 | $1.47B | ★★★★★★ |
Smith Micro Software (NasdaqCM:SMSI) | $0.76 | $12.8M | ★★★★☆☆ |
Global Self Storage (NasdaqCM:SELF) | $4.94 | $57.02M | ★★★★★☆ |
Kiora Pharmaceuticals (NasdaqCM:KPRX) | $2.60 | $7.88M | ★★★★★★ |
Flexible Solutions International (NYSEAM:FSI) | $3.86 | $52.61M | ★★★★★★ |
TETRA Technologies (NYSE:TTI) | $2.36 | $330.99M | ★★★★☆☆ |
BAB (OTCPK:BABB) | $0.775 | $5.59M | ★★★★★☆ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $213.14M | ★★★★★★ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.7022 | $60.57M | ★★★★★☆ |
Click here to see the full list of 790 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
AirJoule Technologies
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: AirJoule Technologies Corporation specializes in atmospheric renewable energy and water harvesting technologies, with a market cap of approximately $268.79 million.
Operations: No specific revenue segments are reported for AirJoule Technologies Corporation.
Market Cap: $268.79M
AirJoule Technologies, with a market cap of US$268.79 million, has transitioned to profitability, reporting a net income of US$215.7 million for 2024 after a prior loss. Despite having no significant revenue streams and being pre-revenue, the company benefits from strong short-term asset coverage over liabilities but faces challenges with long-term liabilities totaling US$113.7 million. The lack of debt is advantageous; however, its high volatility and inexperienced management team may pose risks. Recent financial activities include a $30 million private placement and shelf registration for additional capital raising efforts worth $30.47 million.
Shattuck Labs
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Shattuck Labs, Inc. is a biotechnology company focused on developing antibodies for treating inflammatory and immune-mediated diseases, with a market cap of $35.11 million.